March 22, 2017

CMFRI[**Expression of interst – ANTIHYPERCHOLESTEROLEMIC EXTRACT – CMFRI, Cochin, Kerala**]

CMFRI, Cochin invites Expression of Interest (EoI) to out license nutraceutical product **Cadalmin™ Antihypercholesterolemic extract to combat dyslipidemia and obesity*developed** by the Institute form registered companies with proven track record. The nutraceutical product has been scientifically evaluated and all research documentation is available with the Institute.

* Bioactive pharmacophore leads from seaweeds were used to develop the nutraceutical product, and were found to inhibit hydroxymethyl glutaryl coenzyme A reductase, various target receptors and other rate limiting enzymes, which are responsible to cause obesity and dyslipidemia. Cadalmin™ ACe can be administered to regulate clinical indicators leading to dyslipidemia or obesity, total adipose tissue and visceral fat, triglycerides, cholesterol, both good and bad, known as HDL, VLDL and LDL. Cadalmin™ ACe contains 100% natural marine bioactive ingredients from selected seaweeds by a patented technology, and would be made available in 400 mg capsules. Cadalmin™ ACe is the only product made by 100% natural marine bioactive ingredients from seaweeds as a natural remedy of obesity and dyslipidemia. Time dependent shelf life studies were conducted to identify the changes in bioactivity profile of the product in an accelerated shelf-life study, which revealed that no significant reduction of the activities and the content of active principles of the formulation after the end of study period. Large scale extraction of the active principles from the raw material was optimized in a factory unit. Preclinical trials showed no toxicity related significant changes in renal or hepatic function, hematological indices and serum biochemical parameters in the experimental subjects. The results demonstrate a lack of test substance-related general organ or systemic toxicity following oral administration at a dose as high as 2000 mg/kg/d. **The total yield of the active principles from the raw material in the factory unit was found to be greater than 20%, which demonstrated the commercial feasibility of the nutraceutical product**.

Interested registered companies (private or public) with proven track record may contact or send expression of interest by post and email (director@cmfri.org.in) in the prescribed format to the following address within 21 days of publication of this advertisement.

The Director, Central Marine Fisheries Research Institute
Ernakulam North P.O.; Kochi-18, Kerala

Format for Expression of Interest (EoI)

Name of the firm	Address	Brief profile of the firm concerned	Licence Fee (Onetime payment for a period….years)	Royalty (% of profit that can be shared with CMFRI)	Any other mode of collaboration/licensing with detailed justification

Terms and conditions

- The company should optimize the product production according to CMFRI inputs
- Bear all costs involved in trial runs
- The company will also have the exclusive marketing rights
- Exclusive licensee will have R & D support of CMFRI during the period of licence
- Formulations and source of all raw material will be provided by the Institute
- **The highest bidder will be selected for entering into a memorandum of understanding (MoU)**
- Selection of the bidders may be also at the discretion of the Director CMFRI, if required
- There is no bidding fee and the company with whom CMFRI enters into an MoU shall be published in the website of CMFRI www.cmfri.org.in within 60 days of signing of the MoU
- An existing licensee of CMFRI should appraise the worth of the earlier out-licensed products.
- Correspondences from unsuccessful bidders cannot be entertained.

Director CMFRI Cochin